U.S. FDA Approves RINVOQ® to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis Pharmaceutical Investing
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product Pharmaceutical Investing
UNIVERSAL IBOGAINE ANNOUNCES WORLD-CLASS CLINICAL TRIAL PARTNERS IN ADVANCE OF CLINICAL TRIAL APPLICATION FOR IBOGAINE IN OPIOID USE DISORDER Pharmaceutical Investing
Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders Pharmaceutical Investing
Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering Pharmaceutical Investing
Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms Pharmaceutical Investing
Positive Top-Line Results of Pfizer's Phase 3 Study Exploring Coadministration of PREVNAR 20 With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released Life Science Investing
Jamieson Wellness Celebrates a Century of Improving the World's Health and Wellness Life Science Investing
AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025 Pharmaceutical Investing
Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference Pharmaceutical Investing
